Access to the Dapivirine Vaginal Ring: A timeline on progress
CAB-LA Trials at a Glance
This infographic shares a breakdown of the current injectable CAB for PrEP trials including ongoing sub-studies.
Time to Develop a Vaccine
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphic is excerpted from Vaccines by the Numbers: Trials, discoveries, money and more.
Efficacy Study Design
This graphic details the trial design behind HPTN 083 and HPTN 084, two-large scale efficacy trials testing cabotegravir, an antiretroviral formulated as an injectable for long-lasting pre- exposure prophylaxis (PrEP).
To learn more, read An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP.
Access to the Dapivirine Vaginal Ring: A timeline on progress
This infographic shows the timeline of progress for end user access to Dapivirine Vaginal Ring.
PEPFAR-Funded PrEP and VMMC Services in 14 Priority Countries
This infographic shows that PEPFAR’s increased investment and creation of a budget code resulted in improved scale-up of VMMC (VMMC). A budget code could have the same impact if applied to PrEP initiations.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.
Broadly Neutralizing Antibody Combinations
As with antiretroviral combinations used in treatment, passive immunization of broadly neutralizing antibodies for prevention may require two or more bNAbs that target different parts of the virus. This graphic outlines the bNAb combinations being explored in early clinical studies.